Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Brufsky

Showing results (1-10 of 192) with videos related to

Pageof 20
Sort By:
The Breast Journal|July 3, 2013
Precision oncology in breast cancer: better than ever, or less than before?Adam Brufsky
The Lancet. Oncology|August 10, 2016
Is there room for bevacizumab in metastatic breast cancer?Adam Brufsky
The Lancet. Oncology|June 29, 2011
Adjuvant bisphosphonates for early-stage breast cancerAdam Brufsky
Seminars in Oncology|May 30, 2006
Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST updateAdam Brufsky
Experimental Hematology & Oncology|March 28, 2017
<i>nab</i>-Paclitaxel for the treatment of breast cancer: an update across treatment settingsAdam Brufsky
Journal of Medical Virology|April 21, 2020
Distinct viral clades of SARS-CoV-2: Implications for modeling of viral spreadAdam Brufsky
Journal of Medical Virology|April 16, 2020
Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemicAdam Brufsky
American Journal of Clinical Oncology|August 14, 2009
Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of careAdam Brufsky
The Lancet. Oncology|December 3, 2014
Length of chemotherapy and use of bevacizumab for breast cancerAdam Brufsky
The Lancet. Oncology|July 6, 2017
TACT2: improving treatment tolerability in early breast cancerAju Mathew, Adam Brufsky
Pageof 20

Showing results (1-10 of 192) with videos related to

Sort By:
Pageof 20
The Breast Journal|July 3, 2013
Precision oncology in breast cancer: better than ever, or less than before?Adam Brufsky
The Lancet. Oncology|August 10, 2016
Is there room for bevacizumab in metastatic breast cancer?Adam Brufsky
The Lancet. Oncology|June 29, 2011
Adjuvant bisphosphonates for early-stage breast cancerAdam Brufsky
Seminars in Oncology|May 30, 2006
Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST updateAdam Brufsky
Experimental Hematology & Oncology|March 28, 2017
<i>nab</i>-Paclitaxel for the treatment of breast cancer: an update across treatment settingsAdam Brufsky
Journal of Medical Virology|April 21, 2020
Distinct viral clades of SARS-CoV-2: Implications for modeling of viral spreadAdam Brufsky
Journal of Medical Virology|April 16, 2020
Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemicAdam Brufsky
American Journal of Clinical Oncology|August 14, 2009
Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of careAdam Brufsky
The Lancet. Oncology|December 3, 2014
Length of chemotherapy and use of bevacizumab for breast cancerAdam Brufsky
The Lancet. Oncology|July 6, 2017
TACT2: improving treatment tolerability in early breast cancerAju Mathew, Adam Brufsky
Pageof 20